Toxicogenomics of A375 human malignant melanoma cells treated with arbutin

Journal of Biomedical Science

Volumn 14, Issue 1, 2007, Pages 87-105

  Cheng, Sun Long ^a   Liu, Rosa Huang ^a   Sheu, Jin Nan ^a   Chen, Shui Tein ^b,c   Sinchaikul, Supachok ^b   Tsay, Gregory Jiazer ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

A375 cells; Arbutin; DNA microarray; Gene expression; Toxicogenomics

Indexed keywords

ARBUTIN;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL COMPOSITION; CELL CYCLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA MICROARRAY; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION PROFILING; GENE REPRESSION; GENOTOXICITY; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TOXICOGENETICS; UNINDEXED SEQUENCE;

ARBUTIN; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SKIN NEOPLASMS; TOXICOGENETICS;

EID: 33847106425     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1007/s11373-006-9130-6     Document Type: Article

References (44)

1. Tomita K., Fukuda M. and Kawasaki K., Mechanism of arbutin inhibitory effect on melanogenesis and effect on the human skin with cosmetic use. Fragrance J. 6: 72-77, 1990.
2. Maeda K. and Fukuda M., Arbutin: mechanism of its depigmenting action in human melanocyte culture. J. Pharmacol. Exp. Ther. 276: 765-769, 1996.
3. Ichihashi M., Funasaka Y., Ohashi A., Chacraborty A., Ahmed N.U., Ueda M. and Osawa T., The inhibitory effect of DL-alpha-tocopheryl ferulate in lecithin on melanogenesis. Anticancer Res. 19: 3769-3774, 1999.
4. Sugimoto K.S., Nishimura T., Nomura K., Sugimoto K. and Kuriki T., Inhibitory effects of α-arbutin on melanin synthesis in cultured human melanoma cells and a three-dimensional human skin model. Biol. Pharm. Bull. 27: 510-514, 2004.
5. Brem R., Hildebrandt T., Jarsch M., van Muijen G.N. and Weidle U.H., Identification of metastasis-associated genes by transcriptional profiling of a metastasizing versus a non-metastasizing human melanoma cell line. Anticancer Res. 21: 1731-1740, 2001.
6. de Wit N.J., Burtscher H.J., Weidle U.H., Ruiter D.J. and van Muigen G.N., Differentially expressed genes identified in human melanoma cell lines with different metastatic behavior using high-density oligonucleotide arrays. Melanoma Res. 12: 57-69, 2002.
7. Kunz M., Ibrahim S.M., Koczan D., Scheid S., Thiesen H.J. and Gross G., DNA microarray technology and its applications in dermatology. Exp. Dermatol. 13: 593-606, 2004.
8. Loveland B.E., Johns T.G., Mackay I.R., Vaillant F., Wang Z.X. and Hertzog P.J., Validation of the MTT dye assay for enumeration of cells in proliferative and antiproliferative assays. Biochem. Int. 27: 501-510, 1992.
9. Dudoit S., Yang Y.H., Speed T.P. and Callow M.J., Statistical methods for identifying genes with differential expression in replicated cDNA microarray experiments. Stat. Sin. 12: 111-139, 2002.
10. Tiedtke J., Morel J. and Marks O., Depigmentation factor bioflavonoids-a safe and effective skin lightener based on encapsulated citrus bioflavonoids. Cosmetochem 2: 12-17, 2004.
11. Cheng S.L., Liu R.H., Sheu J.N., Chen S.T., Sinchaikul S. and Tsay G.J., Toxicogenomics of kojic acid on gene expression profiling of A375 human malignant melanoma cells. Biol. Pharm. Bull. 29: 655-669, 2006.
12. Bellacosa A., Kumar C.C., Di Cristofano A. and Testa J.R., Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv. Cancer Res. 94: 29-86, 2005.
13. Vivanco I. and Sawyers C.L., The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer. 2: 489-501, 2002.
14. Song G., Ouyang G. and Bao S., The activation of Akt/PKB signaling pathway and cell survival. J. Cell. Mol. Med. 9: 59-71, 2005.
15. Laprise P., Langlois M.J., Boucher M.J., Jobin C. and Rivard N., Down-regulation of MEK/ERK signaling by E-cadherin-dependent PI3K/Akt pathway in differentiating intestinal epithelial cells. J. Cell. Physiol. 199: 32-39, 2004.
16. Parsa A.T. and Holland E.C., Cooperative translational control of gene expression by Ras and Akt in cancer. Trends Mol. Med. 10: 607-613, 2004.
17. Giehl K., Oncogenic Ras in tumour progression and metastasis. Biol. Chem. 386: 193-205, 2005.
18. Robertson G.P., Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev. 24: 273-285, 2005.
19. Liu X., Shi Y., Han E.K., Chen Z., Rosenberg S.H., Giranda V.L., Luo Y. and Ng S.C., Downregulation of Akt1 inhibits anchorage-independent cell growth and induces apoptosis in cancer cells. Neoplasia 3: 278-286, 2001.
20. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S. and Takada Y., Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 24: 2783-2840, 2004.
21. Liu H., Radisky D.C., Nelson C.M., Zhang H., Fata J.E. and Roth R.A., Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proc. Natl. Acad. Sci. USA 103: 4134-4139, 2006.
22. Balsara B.R., Pei J., Mitsuuchi Y., Page R., Klein-Szanto A., Wang H., Unger M. and Testa J.R., Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25: 2053-2059, 2004.
23. Ruggeri B.A., Huang L., Wood M., Cheng J.Q. and Testa J.R., Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol. Carcinog. 21: 81-86, 1998.
24. Fernandes M.J., Iscove N.N., Gingras G. and Calabretta B., Identification and characterization of the gene for a novel c-type lectin (CLECSF7) that maps near the natural killer gene complex on human chromosome 12. Genomics 69: 263-270, 2000.
25. 2+-dependent animal lectins. Prog. Nucl. Acid Res. Mol. Biol. 45: 207-232, 1993.
26. McGreal E.P., Miller J.L. and Gordon S., Ligand recognition by antigen-presenting cell C-type lectin receptors. Curr. Opin. Immunol. 17: 18-24, 2005.
27. Kemp T.J., Elzey B.D. and Griffith T.S., Plasmacytoid dendritic cell-derived IFN-α induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J. Immunol. 171: 212-218, 2003.
28. Santini S.M., Pucchio T.D., Lapenta C., Parlato S., Logozzi M. and Belardelli F., A new type I IFN-mediated pathway for the rapid differentiation of monocytes into highly active dendritic cells. Stem Cells 21: 357-362, 2003.
29. Arce I., Roda-Navarro P., Montoya M.C., Hernanz-Falcon P., Puig-Kroger A. and Fernandez-Ruiz E., Molecular and genomic characterization of human DLEC, a novel member of the C-type lectin receptor gene family preferentially expressed on monocyte-derived dendritic cells. Eur. J. Immunol. 31: 2733-2740, 2001.
30. Eswarakumar V.P., Lax I. and Schlessinger J., Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16: 139-149, 2005.
31. L'Hote C.G. and Knowles M.A., Cell responses to FGFR3 signaling: growth, differentiation and apoptosis. Exp. Cell. Res. 304: 417-431, 2005.
32. Logie A., Dunois-Larde C., Rosty C., Levrel O., Blanche M., Ribeiro A., Gasc J.M., Jarcano J., Werner S., Sastre-Garau X., Thiery J.P. and Radvanyi F., Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Human Mol. Genet. 14: 1153-1160, 2005.
33. Pandit S.G., Govindraj P., Sasse J., Neame P.J. and Hassell J.R., The fibroblast growth factor receptor, FGFR3, forms gradients of intact and degraded protein across the growth plate of developing bovine ribs. Biochem. J. 361: 231-241, 2002.
34. Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A., Kuehl W.M. and Bergsagel P.L., Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 97: 729-736, 2001.
35. Qian S., Somlo G., Zhou B., Zhu L., Mi S., Mo X., Cheung E.M., Qiu W., Lin R.J., Rossi J., Holtz M., Chu P. and Yen Y., Ribozyme cleavage leads to decreased expression of fibroblast growth factor receptor 3 in human multiple myeloma cells, which is associated with apoptosis and downregulation of vascular endothelial growth factor. Oligonucleotides 15: 1-11, 2005.
36. Zhu L., Somlo G., Zhou B., Shao J., Bedell V., Slovak M.L., Liu X., Luo J. and Yen Y., Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma. Mol. Cancer Ther. 4: 787-798, 2005.
37. He X., Semenov M., Tamai K. and Zeng X., LDL receptor-related proteins 5 and 6 in Wnt/β-catenin signaling: arrows point the way. Development 131: 1663-1677, 2004.
38. Li Y., Lu W., He X., Schwartz A.L. and Bu G., LRP6 expression promotes cancer cell proliferation and tumorigenesis by altering β-catenin subcellular distribution. Oncogene 23: 9129-9135, 2004.
39. Tamai K., Semenov M., Kato Y., Spokony R., Liu C., Katsuyama Y., Hess F, Saint-Jeannet J.P. and He X., LDL-receptor-related proteins in Wnt signal transduction. Nature 407: 530-535, 2000.
40. Benhaj K., Akcali K.C. and Ozturk M., Redundant expression of canonical Wnt ligands in human breast cancer cell lines. Oncol. Rep. 15: 701-707, 2006.
41. Wodarz A. and Nusse R., Mechanisms of Wnt signaling in development. Annu. Rev. Cell. Dev. Biol. 14: 59-88, 1998.
42. Giles R.H., van Es J.H. and Clevers H., Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta 1653: 1-24, 2003.
43. Lustig B. and Behrens J., The Wnt signaling pathway and its role in tumor development. J. Cancer Res. Clin. Oncol. 129: 199-221, 2003.
44. Quaiser T., Anton R. and Kuhl M., Kinases and G proteins join the Wnt receptor complex. Bioessays 28: 339-343, 2006.